Vigil Neuroscience, Inc. (VIGL) NASDAQ
8.05
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vigil Neuroscience, Inc.
Address
1 Broadway
Watertown, MA 02142
United States of America (the)
Phone
857 254 4445
Website
Sector
Healthcare
Industry
Biotechnology
Employees
69
First IPO Date
January 07, 2022
Key Executives
| Name | Title | Pay | Year Born |
| Ivana Magovcevic-Liebisch | President, Chief Executive Officer & Director | 940,700 | 1967 |
| David Gray | Chief Scientific Officer | 601,566 | 1975 |
| Jennifer Ziolkowski | Chief Financial Officer | 650,888 | 1975 |
| Petra Kaufmann | Chief Medical Officer | 665,897 | 1966 |
| Eric Brophy | Senior Manager of Information Technology | 0 | N/A |
| Kevin Durfee | Vice President & Head of Information Technology | 0 | N/A |
| Charles J. Democko | Senior Vice President, Regulatory Affairs & Quality | 0 | 1955 |
| Evan A. Thackaberry | Senior Vice President & Head of Early Development | 0 | 1973 |
| April Effort | Vice President & Head of Corporate Development | 0 | N/A |
| Leah Gibson | Vice President of Investor Relations and Corporate Communications | 0 | N/A |
| Sharon Morani | Senior Director of Facilities & Operations | 0 | N/A |
| Weeteck Yeo | Senior Vice President of Strategic Operations | 0 | N/A |
| Christian Mirescu | Senior Vice President & Head of Neuroimmunology | 0 | N/A |
| Ommer Chohan | Secretary | 0 | N/A |
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
